

## 4 LITERATURVERZEICHNIS

1. Ortqvist A, Hedlund J, and Kalin M. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. *Semin Respir Crit Care Med* 2005; 26: 563-574.
2. Monto AS. Acute respiratory infection in children of developing countries: challenge of the 1990s. *Rev Infect Dis* 1989; 11: 498-505.
3. Mandell LA. Epidemiology and etiology of community-acquired pneumonia. *Infect Dis Clin North Am* 2004; 18: 761-76, vii.
4. Lynch JPII. Hospital-acquired pneumonia: risk factors, microbiology, and treatment. *Chest* 2001; 119: 373S-384S.
5. Chastre J, Trouillet JL, Vuagnat A, Joly-Guillou ML, Clavier H, Dombret MC, and Gibert C. Nosocomial pneumonia in patients with acute respiratory distress syndrome. *Am J Respir Crit Care Med* 1998; 157: 1165-1172.
6. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, and Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. *Am J Med* 1993; 94: 281-288.
7. Marrie TJ. Community-acquired pneumonia. *Clin Infect Dis* 1994; 18: 501-513.
8. Dixon RE. Economic costs of respiratory tract infections in the United States. *Am J Med* 1985; 78: 45-51.
9. Hammerschmidt S, Wolff S, Hocke A, Rosseau S, Muller E, and Rohde M. Illustration of pneumococcal polysaccharide capsule during adherence and invasion of epithelial cells. *Infect Immun* 2005; 73: 4653-4667.
10. Camara M, Mitchell TJ, Andrew PW, and Boulnois GJ. Streptococcus pneumoniae produces at least two distinct enzymes with neuraminidase activity: cloning and expression of a second neuraminidase gene in Escherichia coli. *Infect Immun* 1991; 59: 2856-2858.
11. Rosenow C, Ryan P, Weiser JN, Johnson S, Fontan P, Ortqvist A, and Masure HR. Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. *Mol Microbiol* 1997; 25: 819-829.
12. Sampson JS, O'Connor SP, Stinson AR, Tharpe JA, and Russell H. Cloning and nucleotide sequence analysis of psaA, the Streptococcus pneumoniae gene encoding a 37-kilodalton protein homologous to previously reported Streptococcus sp. adhesins. *Infect Immun* 1994; 62: 319-324.
13. McDaniel LS, Sheffield JS, Delucchi P, and Briles DE. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. *Infect Immun* 1991; 59: 222-228.

14. Feldman C, Mitchell TJ, Andrew PW, Boulnois GJ, Read RC, Todd HC, Cole PJ, and Wilson R. The effect of *Streptococcus pneumoniae* pneumolysin on human respiratory epithelium in vitro. *Microb Pathog* 1990; 9: 275-284.
15. Paton JC, Andrew PW, Boulnois GJ, and Mitchell TJ. Molecular analysis of the pathogenicity of *Streptococcus pneumoniae*: the role of pneumococcal proteins. *Annu Rev Microbiol* 1993; 47: 89-115.
16. Balachandran P, Hollingshead SK, Paton JC, and Briles DE. The autolytic enzyme LytA of *Streptococcus pneumoniae* is not responsible for releasing pneumolysin. *J Bacteriol* 2001; 183: 3108-3116.
17. Austrian R. The pneumococcus at the millennium: not down, not out. *J Infect Dis* 1999; 179 Suppl 2: S338-S341.
18. Tilghman RC and Finland M. Clinical significance of bacteremia in pneumococcal pneumonia. *Arch Intern Med* 1937; 59: 602-619.
19. Hirschtick RE, Glassroth J, Jordan MC, Wilcosky TC, Wallace JM, Kvale PA, Markowitz N, Rosen MJ, Mangura BT, and Hopewell PC. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. *N Engl J Med* 1995; 333: 845-851.
20. Janoff EN, O'Brien J, Thompson P, Ehret J, Meiklejohn G, Duvall G, and Douglas JM, Jr. *Streptococcus pneumoniae* colonization, bacteremia, and immune response among persons with human immunodeficiency virus infection. *J Infect Dis* 1993; 167: 49-56.
21. Kalin M. Pneumococcal serotypes and their clinical relevance. *Thorax* 1998; 53: 159-162.
22. Butler JC, Breiman RF, Lipman HB, Hofmann J, and Facklam RR. Serotype distribution of *Streptococcus pneumoniae* infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine. *J Infect Dis* 1995; 171: 885-889.
23. Peltola H, Booy R, and Schmitt HJ. What can children gain from pneumococcal conjugate vaccines? *Eur J Pediatr* 2004; 163: 509-516.
24. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, and Schuchat A. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. *N Engl J Med* 2003; 348: 1737-1746.
25. Henriques NB, Kalin M, Ortqvist A, Akerlund T, Liljequist BO, Hedlund J, Svenson SB, Zhou J, Spratt BG, Normark S, and Kallenius G. Dynamics of penicillin-susceptible clones in invasive pneumococcal disease. *J Infect Dis* 2001; 184: 861-869.
26. Pons JL, Mandement MN, Martin E, Lemort C, Nouvellon M, Mallet E, and Lemeland JF. Clonal and temporal patterns of nasopharyngeal penicillin-

- susceptible and penicillin-resistant *Streptococcus pneumoniae* stains in children attending a day care center. *J Clin Microbiol* 1996; 34: 3218-3222.
27. Bruyn GA. Pneumococcal immunisation and the healthy elderly. *Lancet* 1992; 340: 1418.
  28. Obaro SK, Adegbola RA, Banya WA, and Greenwood BM. Carriage of pneumococci after pneumococcal vaccination. *Lancet* 1996; 348: 271-272.
  29. Griffith F. The significance of pneumococcal types. *J Hyg* 1928; 27: 113-159.
  30. Coffey TJ, Enright MC, Daniels M, Morona JK, Morona R, Hryniewicz W, Paton JC, and Spratt BG. Recombinational exchanges at the capsular polysaccharide biosynthetic locus lead to frequent serotype changes among natural isolates of *Streptococcus pneumoniae*. *Mol Microbiol* 1998; 27: 73-83.
  31. Lynch JP, III and Zhanel GG. Escalation of antimicrobial resistance among *Streptococcus pneumoniae*: implications for therapy. *Semin Respir Crit Care Med* 2005; 26: 575-616.
  32. Nesin M, Ramirez M, and Tomasz A. Capsular transformation of a multidrug-resistant *Streptococcus pneumoniae* in vivo. *J Infect Dis* 1998; 177: 707-713.
  33. Strieter RM, Belperio JA, and Keane MP. Host innate defenses in the lung: the role of cytokines. *Curr Opin Infect Dis* 2003; 16: 193-198.
  34. Hippenstiel S, Opitz B, Schmeck B, and Suttorp N. Lung epithelium as a sentinel and effector system in pneumonia - molecular mechanisms of pathogen recognition and signal transduction. *Respiratory Research* 2006; 7: 97.
  35. Schmeck B, Zahlten J, Moog K, van LV, Huber S, Hocke AC, Opitz B, Hoffmann E, Kracht M, Zerrahn J, Hammerschmidt S, Rosseau S, Suttorp N, and Hippenstiel S. *Streptococcus pneumoniae*-induced p38 MAPK-dependent phosphorylation of RelA at the interleukin-8 promoter. *J Biol Chem* 2004; 279: 53241-53247.
  36. Schmeck B, Huber S, Moog K, Zahlten J, Hocke AC, Opitz B, Hammerschmidt S, Mitchell TJ, Kracht M, Rosseau S, Suttorp N, and Hippenstiel S. Pneumococci induced TLR- and Rac1-dependent NF- $\kappa$ B-recruitment to the IL-8 promoter in lung epithelial cells. *Am J Physiol Lung Cell Mol Physiol* 2006; 290: L730-L737.
  37. Strieter RM. Interleukin-8: a very important chemokine of the human airway epithelium. *Am J Physiol Lung Cell Mol Physiol* 2002; 283: L688-L689.
  38. Zlotnik A and Yoshie O. Chemokines: a new classification system and their role in immunity. *Immunity* 2000; 12: 121-127.
  39. Romagnani S. Induction of TH1 and TH2 responses: a key role for the 'natural' immune response? *Immunol Today* 1992; 13: 379-381.
  40. Fehrenbach H. Alveolar epithelial type II cell: defender of the alveolus revisited. *Respir Res* 2001; 2: 33-46.

41. Matthay MA, Folkesson HG, and Clerici C. Lung epithelial fluid transport and the resolution of pulmonary edema. *Physiol Rev* 2002; 82: 569-600.
42. Uhal BD. Cell cycle kinetics in the alveolar epithelium. *Am J Physiol* 1997; 272: L1031-L1045.
43. Crouch E and Wright JR. Surfactant proteins a and d and pulmonary host defense. *Annu Rev Physiol* 2001; 63:521-54.: 521-554.
44. Nakamura M, Matute-Bello G, Liles WC, Hayashi S, Kajikawa O, Lin SM, Frevert CW, and Martin TR. Differential response of human lung epithelial cells to fas-induced apoptosis. *Am J Pathol* 2004; 164: 1949-1958.
45. Akira S and Takeda K. Toll-like receptor signalling. *Nat Rev Immunol* 2004; 4: 499-511.
46. Armstrong L, Medford AR, Uppington KM, Robertson J, Witherden IR, Tetley TD, and Millar AB. Expression of functional toll-like receptor-2 and -4 on alveolar epithelial cells. *Am J Respir Cell Mol Biol* 2004; 31: 241-245.
47. Opitz B, Puschel A, Schmeck B, Hocke AC, Rosseau S, Hammerschmidt S, Schumann RR, Suttorp N, and Hippenstiel S. Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized *Streptococcus pneumoniae*. *J Biol Chem* 2004; 279: 36426-36432.
48. Opitz B, Forster S, Hocke AC, Maass M, Schmeck B, Hippenstiel S, Suttorp N, and Krull M. Nod1-mediated endothelial cell activation by *Chlamydia pneumoniae*. *Circ Res* 2005; 96: 319-326.
49. Schmeck B, Beermann W, van LV, Zahlten J, Opitz B, Witzentrath M, Hocke AC, Chakraborty T, Kracht M, Rosseau S, Suttorp N, and Hippenstiel S. Intracellular bacteria differentially regulated endothelial cytokine release by MAPK-dependent histone modification. *J Immunol* 2005; 175: 2843-2850.
50. Rubinfeld H and Seger R. The ERK cascade: a prototype of MAPK signaling. *Mol Biotechnol* 2005; 31: 151-174.
51. Silverman N and Maniatis T. NF- $\kappa$ B signaling pathways in mammalian and insect innate immunity. *Genes & Dev* 2001; 15: 2321-2342.
52. Chen LF and Greene WC. Shaping the nuclear action of NF- $\kappa$ B. *Nat Rev Mol Cell Biol* 2004; 5: 392-401.
53. Hoffmann E, Dittrich-Breiholz O, Holtmann H, and Kracht M. Multiple control of interleukin-8 gene expression. *J Leukoc Biol* 2002; 72: 847-855.
54. Greene CM, Carroll TP, Smith SG, Taggart CC, Devaney J, Griffin S, O'Neill SJ, and McElvaney NG. TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. *J Immunol* 2005; 174: 1638-1646.
55. Monick MM, Yarovinsky TO, Powers LS, Butler NS, Carter AB, Gudmundsson G, and Hunninghake GW. Respiratory syncytial virus up-regulates TLR4 and

- sensitizes airway epithelial cells to endotoxin. *J Biol Chem* 2003; 278: 53035-53044.
56. Cooper P, Potter S, Mueck B, Yousefi S, and Jarai G. Identification of genes induced by inflammatory cytokines in airway epithelium. *Am J Physiol Lung Cell Mol Physiol* 2001; 280: L841-L852.
  57. Chung KF and Barnes PJ. Cytokines in asthma. *Thorax* 1999; 54: 825-857.
  58. N'Guessan PD, Hippenstiel S, Etouem MO, Zahlten J, Beermann W, Lindner D, Opitz B, Witzernath M, Rosseau S, Suttorp N, and Schmeck B. Streptococcus pneumoniae-induced p38 MAPK- and NF- $\kappa$ B-dependent COX-2 expression in human lung epithelium. *Am J Physiol Lung Cell Mol Physiol* 2006; 290: L1131-L1138.
  59. Klockmann MT, Jahn HU, Hippenstiel S, Kramer HJ, and Suttorp N. Interaction of human neutrophils with airway epithelial cells: reduction of leukotriene B4 generation by epithelial cell derived prostaglandin E2. *J Cell Physiol* 1998; 175: 268-275.
  60. Lambrecht BN, Prins JB, and Hoogsteden HC. Lung dendritic cells and host immunity to infection. *Eur Respir J* 2001; 18: 692-704.
  61. Moore BB, Moore TA, and Toews GB. Role of T- and B-lymphocytes in pulmonary host defences. *Eur Respir J* 2001; 18: 846-856.
  62. Kadioglu A and Andrew PW. The innate immune response to pneumococcal lung infection: the untold story. *Trends Immunol* 2004; 25: 143-149.
  63. Delclaux C and Azoulay E. Inflammatory response to infectious pulmonary injury. *Eur Respir J Suppl* 2003; 42:10s-14s.: 10s-14s.
  64. Nicod LP. Pulmonary defence mechanisms. *Respiration* 1999; 66: 2-11.
  65. Hajjar AM, Harowicz H, Liggitt HD, Fink PJ, Wilson CB, and Skerrett SJ. An essential role for non-bone marrow-derived cells in control of Pseudomonas aeruginosa pneumonia. *Am J Respir Cell Mol Biol* 2005; 33: 470-475.
  66. Noulin N, Quesniaux VF, Schnyder-Candrian S, Schnyder B, Maillet I, Robert T, Vargaftig BB, Ryffel B, and Couillin I. Both hemopoietic and resident cells are required for MyD88-dependent pulmonary inflammatory response to inhaled endotoxin. *J Immunol* 2005; 175: 6861-6869.
  67. Hollingsworth JW, Chen BJ, Brass DM, Berman K, Gunn MD, Cook DN, and Schwartz DA. The Critical Role of Hematopoietic Cells in Lipopolysaccharide-induced Airway Inflammation. *Am J Respir Crit Care Med* 2005; 171: 806-813.
  68. Poynter ME, Irvin CG, and Janssen-Heininger YM. A prominent role for airway epithelial NF-kappa B activation in lipopolysaccharide-induced airway inflammation. *J Immunol* 2003; 170: 6257-6265.
  69. Yin MJ, Yamamoto Y, and Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. *Nature* 1998; 396: 77-80.

70. Adcock IM, Caramori G, and Ito K. New insights into the molecular mechanisms of corticosteroids actions. *Curr Drug Targets* 2006; 7: 649-660.
71. Adcock IM, Chung KF, Caramori G, and Ito K. Kinase inhibitors and airway inflammation. *Eur J Pharmacol* 2006; 533: 118-132.
72. Kumar S, Boehm J, and Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. *Nat Rev Drug Discov* 2003; 2: 717-726.
73. Ridley AJ. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. *Trends Cell Biol* 2006; 16: 522-529.
74. Arbibe L, Mira JP, Teusch N, Kline L, Guha M, Mackman N, Godowski PJ, Ulevitch RJ, and Knaus UG. Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. *Nat Immunol* 2000; 1: 533-540.
75. Hippenstiel S, Soeth S, Kellas B, Fuhrmann O, Seybold J, Krull M, Eichel-Streiber C, Goebeler M, Ludwig S, and Suttorp N. Rho proteins and the p38-MAPK pathway are important mediators for LPS-induced interleukin-8 expression in human endothelial cells. *Blood* 2000; 95: 3044-3051.
76. Grassl GA, Kracht M, Wiedemann A, Hoffmann E, Aepfelbacher M, Eichel-Streiber C, Bohn E, and Autenrieth IB. Activation of NF-kappaB and IL-8 by *Yersinia enterocolitica* invasin protein is conferred by engagement of Rac1 and MAP kinase cascades. *Cell Microbiol* 2003; 5: 957-971.
77. Schmeck B, Beermann W, van L, V, Opitz B, Hocke AC, Meixenberger K, Eitel J, Chakraborty T, Schmidt G, Barth H, Suttorp N, and Hippenstiel S. *Listeria monocytogenes* induced Rac1-dependent signal transduction in endothelial cells. *Biochem Pharmacol* 2006; 72: 1367-1374.
78. Shaulian E and Karin M. AP-1 as a regulator of cell life and death. *Nat Cell Biol* 2002; 4: E131-E136.
79. Shen G, Jeong WS, Hu R, and Kong AN. Regulation of Nrf2, NF-kappaB, and AP-1 signaling pathways by chemopreventive agents. *Antioxid Redox Signal* 2005; 7: 1648-1663.
80. Elm C, Rohde M, Vaerman JP, Chhatwal GS, and Hammerschmidt S. Characterization of the interaction of the pneumococcal surface protein SpsA with the human polymeric immunoglobulin receptor (hplgR). *Indian J Med Res* 2004; 119 Suppl: 61-65.
81. Schmeck B, Gross R, N'Guessan PD, Hocke AC, Hammerschmidt S, Mitchell TJ, Rosseau S, Suttorp N, and Hippenstiel S. *Streptococcus pneumoniae*-induced caspase 6-dependent apoptosis in lung epithelium. *Infect Immun* 2004; 72: 4940-4947.
82. Lavrik IN, Golks A, and Krammer PH. Caspases: pharmacological manipulation of cell death. *J Clin Invest* 2005; 115: 2665-2672.

83. Kroemer G and Martin SJ. Caspase-independent cell death. *Nat Med* 2005; 11: 725-730.
84. Fas SC, Fritzsching B, Suri-Payer E, and Krammer PH. Death receptor signaling and its function in the immune system. *Curr Dir Autoimmun* 2006; 9: 1-17.
85. Hotchkiss RS and Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. *Nat Rev Immunol* 2006; 6: 813-822.
86. Hotchkiss RS, Chang KC, Swanson PE, Tinsley KW, Hui JJ, Klender P, Xanthoudakis S, Roy S, Black C, Grimm E, Aspiotis R, Han Y, Nicholson DW, and Karl IE. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. *Nat Immunol* 2000; 1: 496-501.
87. Braun JS, Novak R, Herzog KH, Bodner SM, Cleveland JL, and Tuomanen EI. Neuroprotection by a caspase inhibitor in acute bacterial meningitis. *Nat Med* 1999; 5: 298-302.
88. Grassme H, Kirschnek S, Riethmueller J, Riehle A, von Kurthy G, Lang F, Weller M, and Gulbins E. CD95/CD95 ligand interactions on epithelial cells in host defense to *Pseudomonas aeruginosa*. *Science* 2000; 290: 527-530.
89. Chaby R, Garcia-Verdugo I, Espinassous Q, and Augusto LA. Interactions between LPS and lung surfactant proteins. *J Endotoxin Res* 2005; 11: 181-185.
90. Meyer KC and Zimmerman JJ. Inflammation and surfactant. *Paediatr Respir Rev* 2002; 3: 308-314.
91. Sano H and Kuroki Y. The lung collectins, SP-A and SP-D, modulate pulmonary innate immunity. *Mol Immunol* 2005; 42: 279-287.
92. Yoshida M and Whitsett JA. Interactions between pulmonary surfactant and alveolar macrophages in the pathogenesis of lung disease. *Cell Mol Biol (Noisy-le-grand)* 2004; 50 Online Pub:OL639-48.: OL639-OL648.
93. Griffiths MJ, Bonnet D, and Janes SM. Stem cells of the alveolar epithelium. *Lancet* 2005; 366: 249-260.
94. Tesfaigzi Y. Processes involved in the repair of injured airway epithelia. *Arch Immunol Ther Exp (Warsz )* 2003; 51: 283-288.
95. Shimabukuro DW, Sawa T, and Gropper MA. Injury and repair in lung and airways. *Crit Care Med* 2003; 31: S524-S531.
96. Abreu MT, Fukata M, and Arditi M. TLR signaling in the gut in health and disease. *J Immunol* 2005; 174: 4453-4460.
97. Cario E and Podolsky DK. Intestinal epithelial TOLLerance versus inTOLLerance of commensals. *Mol Immunol* 2005; 42: 887-893.

98. Spaan S, Wouters IM, Oosting I, Doekes G, and Heederik D. Exposure to inhalable dust and endotoxins in agricultural industries. *J Environ Monit* 2006; 8: 63-72.
99. Lane SR, Nicholls PJ, and Sewell RD. The measurement and health impact of endotoxin contamination in organic dusts from multiple sources: focus on the cotton industry. *Inhal Toxicol* 2004; 16: 217-229.
100. Guillot L, Medjane S, Le Barillec K, Balloy V, Danel C, Chignard M, and Si-Tahar M. Response of human pulmonary epithelial cells to lipopolysaccharide involves Toll-like receptor 4 (TLR4)-dependent signaling pathways: evidence for an intracellular compartmentalization of TLR4. *J Biol Chem* 2004; 279: 2712-2718.
101. Jia HP, Kline JN, Penisten A, Apicella MA, Gioannini TL, Weiss J, and McCray PBJ. Endotoxin responsiveness of human airway epithelia is limited by low expression of MD-2. *Am J Physiol Lung Cell Mol Physiol* 2004; 287: L428-L437.
102. Zhang G and Ghosh S. Negative regulation of toll-like receptor-mediated signaling by Tollip. *J Biol Chem* 2002; 277: 7059-7065.
103. Burns K, Clatworthy J, Martin L, Martinon F, Plumpton C, Maschera B, Lewis A, Ray K, Tschopp J, and Volpe F. Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. *Nat Cell Biol* 2000; 2: 346-351.